Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: Results of a prospective multicenter phase II trial

Leukemia

Volumn 12, Issue 10, 1998, Pages 1522-1526

  Kern, W ^a   Braess, J ^a   Grote Metke, A ^b   Kuse, H ^c   Fuchs, R ^d   Hossfeld, D K ^e   Reichle, A ^f   Wormann B ^a   Buchner T ^g   Hiddemann, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d St Antonius Hosp   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Aclarubicin; Acute myeloid leukemia; Etoposide; Refractory disease

Indexed keywords

ACLARUBICIN; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DIARRHEA; DRUG HYPERSENSITIVITY; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INFECTION; LEUKEMIA REMISSION; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; VOMITING;

EID: 17044452000     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401155     Document Type: Article

References (13)

1. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997; 24: 57-69.
2. Rowe JM, Liesveld JL. Treatment and prognostic factors in acute myeloid leukaemia. Baillières Clin Haematol 1996; 9: 87-105.
3. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen Ant R, Lengfelder E, Arlin Z, Büchner T. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744-749.
4. Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer 1997; 79: 59-68.
5. Estey E. Treatment of refractory AML. Leukemia 1996; 10: 932-936.
6. Tapiero H, Boule D, Trincal G, Fourcade A, Lampidis TJ. Potentiation of adriamycin accumulation and effectiveness in adriamycinresistant cells by aclacinomycin A. Leukemia Res 1988; 12: 411-418.
7. Scott CA, Westmacott D, Broadhurst MJ, Thomas GJ, Hall MJ. 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Br J Cancer 1986; 53: 595-600.
8. Dong J, Naito M, Tatsuta T, Seimiya H, Johdo O, Tsuruo T. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol Res 1995; 7:245-252.
9. Tapiero H, Nguyen Ba G, Lampidis TJ. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells. Pathol Biol Paris 1994; 42: 328-337.
10. Bennett JM, Lymann GH, Cassileth PA, Click JH, Oken MM. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1984; 7: 471-473.
11. Ho AD, Brado B, Haas R, Hunstein W. Etoposide in acute leukemia. Past experience and future perspectives. Cancer 1991; 67: 281-284.
12. Rowe JM, Chang AY, Bennett JM. Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood 1988; 71: 992-996.
13. Hiddemann W, Becker K, Grote-Metke A, Kuse R, Bartholomäus A, Reichle A, Meuthen I, Schlag R, Fuchs R, Fuhr HG, Leimer D, Hossfeld DK, Büchner T. Aclacinomycin A/etoposide combination therapy for advanced relapsed acute myeloid leukemia: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Haematol Blood Transf 1992; 34: 458-461.